Impact of Target-Mediated Elimination on the Dose and...

  • Main
  • 2016 / 11
  • Impact of Target-Mediated Elimination on the Dose and...

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Gibbs, John P., Doshi, Sameer, Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Dodds, Michael G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Blom, Dirk
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Journal of Clinical Pharmacology
DOI:
10.1002/jcph.840
Date:
November, 2016
File:
PDF, 941 KB
english, 2016
Conversion to is in progress
Conversion to is failed